Literature DB >> 18773863

Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study.

Gang Chen1, Yi-Wu Dang, Dian-Zhong Luo, Zhen-Bo Feng, Xiao-Ling Tang.   

Abstract

Heparanase plays an important role in invasion and metastasis of tumor cells. In this study, we explored the expression and clinicopathological significance of heparanase protein in hepatocellular carcinogenesis to investigate their roles in invasion and the relationship between biological behavior and prognosis of hepatocellular carcinoma (HCC) in tissue microarrays (TMAs). Heparanase expression was examined by immunohistochemistry in TMAs comprising 120 cases of HCC, 48 cases of adjacent tumor liver, 62 cases of cirrhosis, and 23 cases of normal liver tissues. Statistical analyses were determined to access the correlation between heparanase expression and the clinicopathological features of HCC. The results showed a positive level of heparanase in HCC tissues that was significantly higher than that in adjacent tumor liver, cirrhosis, and normal liver tissue. Heparanase was expressed lower in clinical TNM stages I and II than in III and IV. Moreover, the expression of heparanase in cases without metastasis within 20 months was statistically lower than in those with metastasis. Furthermore, heparanase expression in groups of alpha-fetoprotein (AFP) > or = 400 microg/L, portal vein tumor emboli, multiple tumor nodes, and tumor diameter > or = 5 cm were significantly higher than those of corresponding groups, while it was not associated with patients' age, sex, histological classification, cirrhosis, or tumor capsular infiltration. In conclusion, TMA is a powerful tool for the rapid identification of molecular alterations in HCC. The overexpression of heparanase may play an important role in hepatocarcinogenesis, progression, and metastases of HCC. It could serve as a determining factor for clinical prognosis and curative effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18773863     DOI: 10.3727/096504008785114138

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  15 in total

1.  Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Authors:  Yang Yang; Yongsheng Ren; Vishnu C Ramani; Li Nan; Larry J Suva; Ralph D Sanderson
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

Review 2.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

3.  PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.

Authors:  Boris Winterhoff; Luisa Freyer; Edward Hammond; Shailendra Giri; Susmita Mondal; Debarshi Roy; Attila Teoman; Sally A Mullany; Robert Hoffmann; Antonia von Bismarck; Jeremy Chien; Matthew S Block; Michael Millward; Darryn Bampton; Keith Dredge; Viji Shridhar
Journal:  Eur J Cancer       Date:  2015-03-05       Impact factor: 9.162

4.  Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease.

Authors:  Jian Ruan; Timothy N Trotter; Li Nan; Rongcheng Luo; Amjad Javed; Ralph D Sanderson; Larry J Suva; Yang Yang
Journal:  Bone       Date:  2013-07-27       Impact factor: 4.398

5.  PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models.

Authors:  K Dredge; E Hammond; P Handley; T J Gonda; M T Smith; C Vincent; R Brandt; V Ferro; I Bytheway
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

6.  Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues.

Authors:  Minhua Rong; Rongquan He; Yiwu Dang; Gang Chen
Journal:  Ups J Med Sci       Date:  2013-10-31       Impact factor: 2.384

7.  Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.

Authors:  Yiwu Dang; Dianzhong Luo; Minhua Rong; Gang Chen
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

8.  Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.

Authors:  Minhua Rong; Gang Chen; Yiwu Dang
Journal:  BMC Cancer       Date:  2013-01-16       Impact factor: 4.430

9.  Synergistic effect of MiR-146a mimic and cetuximab on hepatocellular carcinoma cells.

Authors:  Suning Huang; Rongquan He; Minhua Rong; Yiwu Dang; Gang Chen
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

Review 10.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.